LES membership carries with it many great benefits. From networking to education to mentorship, this society has much to offer licensing professionals at all stages of their careers. We are particularly proud of the Royalty Rates and Deal Terms Surveys that the team produces, which provide immense value to organizations across industries and help inform their efforts to protect and price intellectual property. As such, we’re delighted to share that the LES Global Life Sciences Royalty Rates and Deal Terms Survey – 2024 is now available for purchase and general use.

This survey was produced in conjunction with the Licensing Executives Society International (LESI) and was made possible by our generous sponsor, Mintz (Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.). The survey also depended on the efforts of each LES survey contributor. Last year, we asked for public input to populate the survey with recent actual deal data, and the community stepped up. During the input period, we received 149 complete responses for analysis and inclusion in this report. It is this data that makes the surveys useful, and we thank all participants for their time and effort. Thank you as well to Vault Consulting, the firm commissioned to conduct the survey, for its professional execution.

A History of Strong Participation
The first Life Sciences Survey was published in 2008 and helped shape the format, content and execution of future LES surveys. The survey has been conducted eight times since then. Over the course of the published Life Sciences Surveys, 1,070 effective deal samples have been collected. This high level of input represents the largest sample size accumulated among all LES USA & Canada surveys and helps produce a robust benchmarking tool for IP and licensing professionals.

Ongoing Value
The data generated from this year’s surveys will be combined with historical data from past surveys to provide LES members with not only an update on current market trends, but also a retrospective look at how licensing practices have evolved over the years. Deal Statistics included:

  • 47% of companies indicated having 1-2 licenses executed in the past 12 months.
  • 86% of reported deals were reported by the licensors.
  • 19% of deals were related to Injectable products, 20% Small Molecule Therapy, and 19% Biological Therapeutic.
  • Anticancer (Oncology), CNS, Immunological, and Infectious Disease were the most prevalent therapeutic area types.

Masterful analysis and organization from the LES team* reveal consistent trends within categories across surveys dating back to 2008, providing further insights into diagnostic and non-human applications. These multi-national surveys have long served as a trusted resource for economic benchmarks defining life sciences deals. The survey reports help explain how licensing deals are structured and why, as well as the rationale behind the licensing of parties and the specific licensing features chosen and used. This information provides a valuable benchmarking tool that IP and licensing professionals depend on to deliver value to their organizations. Use of the survey information also extends to lawyers, corporate finance and investment professionals, and beyond.
This year’s LES Global Life Sciences Royalty Rates and Deal Terms Survey can be downloaded for free by LES members. Non-members can purchase the report for a one-time fee of $795.

Considering LES membership? Now is a great time to join. Gain access to our new survey and myriad other LES membership benefits with an annual fee of just $395 ($195 annually for emerging leaders).

Follow us on Twitter, Facebook and LinkedIn to stay up to date on all things LES.

*The LES team included:
MICHAEL PERHAM, Chair, Howard Hughes Medical Institute

Analysis & Report Committee

  • JAYDE WOOD, Gowling WLG
  • SEAN SHERIDAN, Charles River Associates, Int’l
  • ANISHA JAIPURIA, Charles River Associates, Int’l

Survey Instrument and Promotion Committee

  • JAYDE WOOD, Gowling WLG
  • SEAN SHERIDAN, Charles River Associates, Int’l
  • TRICIA KUHL, Blakes (Blake, Cassels & Graydon LLP)
  • JONATHAN HARRIS, Nutter (Nutter McClennen & Fish LLP)Vault Consulting, LLC
  • IAN SANTO DOMINGO, Managing Director
  • RACHELLE SMITH, Sr. Analyst
Share this article: